About Elcon Drugs and Formulations Limited
Data last updated:
Elcon Drugs and Formulations Limited is a public limited company based in Jaipur, Rajasthan, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 04 January 1994 and has been in existence for over 32 years.
The company is registered with the Registrar of Companies (ROC), Jaipur, under CIN U24232RJ1994PLC007922. Its GSTIN is 08AAACE7948Q1ZU (Rajasthan).
The company has an authorised share capital of ₹80 Lakh and a paid-up capital of ₹77.15 Lakh. It is led by directors including Amit Khandelwal (Whole-Time Director) and Anuradha Khandelwal (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at G – 2 G – 3 G R Tower Hathoj Mod Bindayaka Road, Jaipur, Rajasthan, India – 302012.
As per the financials filed for FY 2024, the company reported a revenue of ₹33.6 Cr, a growth of 104% compared to the previous year. For the same year it recorded a net profit of ₹2.82 Cr (net margin 8.4%) and EBITDA of ₹4.01 Cr (EBITDA margin 11.9%). Revenue has grown at a compounded annual rate (CAGR) of 133% over three years and 47% over five years.
The company has about 10 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹44.69 Lakh and satisfied charges of ₹5.85 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website elcon-drugs-and-formulations-ltd.business.site.
Company details
Contact details
Elcon Drugs and Formulations Limited's registered office is in Jaipur, Rajasthan. Its website is elcon-drugs-and-formulations-ltd.business.site. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Social Media
- Registered AddressG – 2 G – 3 G R Tower Hathoj Mod Bindayaka Road, Jaipur, Rajasthan, India – 302012
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Elcon Drugs and Formulations Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activities of Elcon Drugs and Formulations are trade and support service to organizations. In detail, this covers wholesale trading and other support services to organizations. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | |
| N | Support service to Organizations | N7 | Other support services to organizations |
To see the full business activity and turnover split of Elcon Drugs and Formulations Limited, buy the company report.
Financials of Elcon Drugs and Formulations Limited
FY 2025 filings availableElcon Drugs and Formulations Limited reported revenue of ₹33.6 Cr (up 104% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 47% over five years, including 104% growth in the latest year. EBITDA rose 25% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹4.01 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹2.82 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 11.9% | ||||
| Net Profit Margin | 8.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Elcon Drugs and Formulations Limited, buy the company report.
Board of directors of Elcon Drugs and Formulations Limited
Elcon Drugs and Formulations has 3 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Amit Khandelwal Also directs: Elcon Pharma LLP | Whole-Time Director | 04 Jan 1994 | 32 Years 10 Months | Current |
| Anuradha Khandelwal Also directs: Elcon Pharma LLP | Whole-Time Director | 15 Jul 2015 | 11 Years 3 Months | Current |
| Shiven Khandelwal Also directs: Elcon Pharma LLP | Whole-Time Director | 25 Jan 2020 | 6 Years 9 Months | Current |
Auditor
Elcon Drugs and Formulations Limited is audited by S G A & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S G A & ASSOCIATES | FY 2023 | 007709C |
Shareholding
The shareholding of Elcon Drugs and Formulations Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Elcon Drugs and Formulations Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 05 Feb 2025 | 101077061 | Hdfc Bank Limited | ₹14.69 Lakh | Open | |
| 25 Jan 2001 | 80068290 | State Bank of India | ₹30 Lakh | Open | |
| 30 Sep 2017 | 100145759 | Others | ₹2.25 Cr | Satisfied | |
| 29 Feb 2016 | 10625274 | Tata Capital Financial Services Limited | ₹2 Cr | Satisfied | |
| 15 Oct 2004 | 80068291 | State Bank of India | ₹27 Lakh | Satisfied |
To see the full charge records of Elcon Drugs and Formulations Limited, buy the company report.
Total charge records: 9 View all charges
Legal cases
No court or tribunal cases involving Elcon Drugs and Formulations Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
Elcon Drugs and Formulations Limited has 2 MSME Form 1 returns on record for the period ending Mar 2019, listing 59 overdue payments to 12 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 12)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| Allianz Chemicals | |||
| an individual supplier |
To see the full MSME payment records of Elcon Drugs and Formulations Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Elcon Drugs and Formulations has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 08AAACE7948Q1ZU | Rajasthan | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Elcon Drugs and Formulations Limited, buy the company report.
Recent activity
Elcon Drugs and Formulations Limited has 11 board changes on record since 1994: 7 appointments and 4 cessations. The latest: Radha Govind Khandelwal ceased to be Whole-Time Director on 27 Jan 2020.
19 earlier events are in the company report.
Frequently asked questions
Elcon Drugs and Formulations is an active public limited company based in Jaipur, Rajasthan, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 04 January 1994 (32+ years old) and is registered under CIN U24232RJ1994PLC007922.
Elcon Drugs and Formulations has 3 current directors:
- Amit Khandelwal - Whole-Time Director
- Anuradha Khandelwal - Whole-Time Director
- Shiven Khandelwal - Whole-Time Director
The latest financial statements of Elcon Drugs and Formulations on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Elcon Drugs and Formulations is 08AAACE7948Q1ZU, registered in Rajasthan.
The CIN (Corporate Identification Number) of Elcon Drugs and Formulations is U24232RJ1994PLC007922. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Elcon Drugs and Formulations was incorporated on 04 January 1994, making it 32+ years old. It is registered with the Registrar of Companies, Jaipur.
Radha Govind Khandelwal ceased to be Whole-Time Director on 27 Jan 2020. Ritu Khandelwal ceased to be Whole-Time Director on 27 Jan 2020. Shiven Khandelwal was appointed as Whole-Time Director on 25 Jan 2020. Elcon Drugs and Formulations has 11 board changes on record in total.
Elcon Drugs and Formulations has 2 MSME Form 1 returns on record for the period ending Mar 2019, listing 59 overdue payments to 12 micro and small suppliers. The latest return was filed on 31 May 2019.
Elcon Drugs and Formulations can be reached through the website elcon-drugs-and-formulations-ltd.business.site. Its registered office is in Jaipur, Rajasthan, India.
The registered office of Elcon Drugs and Formulations is at G – 2 G – 3 G R Tower Hathoj Mod Bindayaka Road, Jaipur, Rajasthan, India – 302012.
Elcon Drugs and Formulations operates in the pharma industry, in the drug formulation and development segment.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
